* All times shown in EST

8:00 am
Registration & Morning Coffee

8:50 am Chair’s Opening Remarks

Harnessing the Therapeutic Applications of Modified Exosomes Across Different Indications

9:00 am Novel Exosome-Based Therapies for Treating Colorectal Cancer


  • T cells costimulatory functions are affected by tumor-intrinsic mechanism in colorectal cancer leading to host immune suppression
  • Modified colorectal cancer tumor EVs without immune suppressive microRNAs can stimulate antitumor immunity and has therapeutic potential in advanced disease models
  • Harnessing the immunogenicity of modified tumor EVs can be developed as a novel therapeutic strategy to reduce cancer immunotherapy resistance

9:30 am GMP Manufacturing for Exosome-Based Therapies

  • Davide Zocco Head of Exosomes Development & Site Head, Lonza
  • Marcos Langtry Director of Commercial Development, Allogeneic Cell Therapy, Lonza


  • The critical role of analytics and process development for clinical production
  • An effective process for clinical manufacturing and beyond

10:00 am Diving into the Therapeutic Potential of Engineered Exosomes in Inflammatory Diseases & CNS Disorders


  • Unlocking insights into moving from pre-clinical to clinical stages
  • Leveraging exosomes for the treatment of inflammatory disease in organs including kidney and liver
  • Exploring CNS targeting exosome: a new target technology to deliver exosomes to the CNS

10:30 am
Morning Break & Structured Networking

Track A: Discovery

Unravelling the Enhanced Therapeutic Values of Different Sources of EVs

11:30 am Unlocking the Therapeutic Potential of Cell- Derived Vesicles (CDVs)


  • Enhanced therapeutic outcomes through targeted RNA cargo delivery
  • Unravelling the ability of CDVs to overcome cellular and tissue barriers
  • Unique advantages of CDVs to allow large-scale manufacturing

12:00 pm Cell Reprogramming & Regenerative Medicine Using Extracellular Vesicles

  • David Greening A/Prof & Head of Molecular Proteomics, Baker Heart & Diabetes Institute


  • Quantitative mass spectrometry in defining circulating EVs at proteome and lipidome levels
  • How do EVs and specific regulatory cargo signal in target cells?
  • Defining the EV surface as an interactive platform
  • Strategies for dynamically reprogramming target cells and tissues

Track B: Translation

Progressing Pre-Clinical & Translational Applicability of EVs towards Clinical Development

11:30 am Maximizing the Therapeutic Potential of the SIRP-Exosome in Liver Diseases


  • Maximizing the expression of potential therapeutic proteins on surface of exosomes through the maxisome platform technology
  • Exploring applications of the SIRP-Exosomes in liver diseases
  • Overcoming heterogeneous and complex liver diseases through the SIRP-Exosome

12:00 pm Exosome- Based Therapeutical Solution from “Right” Targets

  • WeiCheng Su Chief Innovation Officer, Exonox Biosciences


  • Development of triple negative breast cancer specific biomarker panel from patients
  • What spell the “right” biomarker(s) for potential metastasis/recurrence
  • Plan to the confirmation of functional biomarkers leading to the druggable targets

12:30 pm
Networking Lunch

Optimizing Production, Storage & Potency of EVs for Improved Bioactivity

1:30 pm Effects of Storage Conditions on EV Bioactivity & Loaded Cargo

  • Steven Jay Associate Professor of Bioengineering, University of Maryland


  • EVs can be loaded with cargo via a variety of endogenous and exogenous methods
  • Storage time and temperature affect intrinsic EV bioactivity as well as the amount and activity of loaded cargo
  • Lyophilization is a viable option for EV storage

2:00 pm Technological & Developmental Aspects of the Production of EVs from Allogeneic Bone Marrow-Derived MSCs


  • Unraveling characterization approaches for EVs from allogeneic bone marrow-derived MSCs
  • Exploring the protein profile of EVs from allogeneic bone marrow-derived MSCs and their impact on continuous wound healing
  • Discuss potency assay development
  • Potential data on new indication

Accelerating Late Stage Clinical Development of EVs & Progress Update

1:30 pm Advancement on Clinical Trials with Amniotic Fluid Extracellular Vesicles


  • Novel source of Perinatal derived Extracellular Vesicles
  • Phase I/II Clinical Trials Protocol
  • Results of a completed Expanded Access Trial

2:00 pm EXO-CD24 (CovenD24) Promise in the Corona Age & Beyond – the Road from an Idea to a Groundbreaking Reality

  • Shiran Shapira Head of Research Laboratory, Health Promotion Center & Integrated Cancer Prevention Center, Tel-Aviv Sourasky Medical Center, Tel-Aviv Sourasky Medical Center


  • How we accelerated the route to clinical phases within 6 months of discovery and launched phase 3 in two years
  • Unravelling the therapeutic potential of EXO-CD24 to treat the most important complication of COVID-19, the cytokine storm and reduce overreaction of the immune system
  • Developing the next steroid- similar (or even better) efficacy without the AEs

2:30 pm
Afternoon Networking Break & Poster Session

Bioengineering Approaches for Effective Payload Manipulation & Cargo Loading

3:15 pm Panel Discussion: Comparing Engineered & Naturally Derived Exosomes for Therapeutic Benefit


  • What are the advantages and limitations of engineering exosomes as therapeutics and as drug delivery vehicles?
  • Linking engineering to the successful loading of cargo

4:15 pm Leveraging Bioengineering Approaches for Exosome-Based Precision Drug Delivery

  • Mei He Assistant Professor, University of Florida


  • Identify key challenges in exosome-based drug delivery
  • Introduce bioengineering solutions to exosome isolation, payload manipulation, and cargo loading
  • Introduce cellular sources for EV production and molecular engineering

4:45 pm Chair’s Closing Remarks

5:00 pm End of Conference Day One